The New Mexico Medical Psilocybin Act establishes a state-regulated framework for psilocybin assisted therapy. The Act intersects with the territorial and governance interests of the 23 federally recognized tribes and Pueblos of New Mexico, whose citizens constitute approximately 12.4% of the state population, the second-highest proportion of any state in the country.

The conditions the Act is designed to address, including major treatment-resistant depression, post-traumatic stress disorder, and substance use disorders, are documented at disproportionately high rates in Indigenous communities, where the legacies of colonization, forced relocation, and intergenerational trauma have shaped the present terrain of behavioral health. The questions the Act raises bear directly on care for the conditions Indigenous communities confront most acutely.

Psilocybin itself is a molecule produced by Psilocybe mushrooms, carried for generations in the ceremonial knowledge of Mazatec and other Indigenous peoples, and isolated and synthesized by Western science only in 1958. As a regulated clinical program takes shape in New Mexico, this initiative supports tribal communities in considering the Act, the state regulatory framework, and the distinction between regulated clinical access and Indigenous ceremonial knowledge, at a pace and in formats that fit each community's own governance processes.

Authentic community deliberation requires spaciousness. This initiative expands the timeline available to tribal nations so that communities can examine the cultural, historical, clinical, and jurisdictional dimensions of the Act with the deliberative attention that sound governance requires, free of the reactive posture a compressed policy environment produces.